Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience Inc.

Alto Neuroscience is redefining psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective medicines, helping patients get better faster. ​

Alto's Precision Psychiatry Platform™ measures biomarkers like EEG and wearable data, behavioral patterns, genetics, and other factors to match patients with the treatment they are most likely to respond to. Our approach matches the right patient with the right Alto drug based on AI-derived brain biomarkers, redefining psychiatry at a time when the world needs it most.

K2 HealthVentures

Tim Kendall

Risk and Return

What If Ventures

Windham Venture Partners

Able Partners

Apeiron Investment Group

Presight Capital

Korify Capital

Stanford University

NJF Capital

Gaingels

Alkeon Capital

Novartis Pharma

Lightswitch Capital

Sobrato Capital

Valor Equity Partners

Vine Ventures

Alpha Wave Ventures

Bioverge

InVivium Capital

Alexandria Venture Investments

Point72 Ventures

Eli Lilly

Franklin Templeton

Alto Neuroscience

To kick off this year’s #MeetTheTeam features, we’re showcasing Khanh Tang, Alto’s Associate Director of Clinical Operations. Khanh’s role is essential in reviewing data and metrics to support the oversight of current projects, as well as planning upcoming studies. When she’s not in the office, Khanh enjoys experiencing new places, cultures, and languages.


Our product candidates in development target core #brain processes, including:

🧠 Cognition
🙂 Emotion and its regulation
💤 Sleep and circadian rhythms

Learn more: https://brnw.ch/21wGjy5

#DYK that our clinical-stage pipeline includes novel drug candidates in #Depression, #PTSD, #Schizophrenia, and other #MentalHealth conditions? Learn more about our pipeline and target indications: https://brnw.ch/21wG7u9


#Psychiatry is an ever-changing field, and treatment options will continue to evolve in 2024. At Alto, we are passionate about developments in the #MentalHealth treatment landscape and furthering our mission to bring personalized, effective treatments to people in need.


Happy holidays from the Alto Team! We're planning to spend this holiday season prioritizing our mental health and spending some time with family and loved ones.


	Dec '22	Mar '23	Jun '23	Sep '23	Dec '23	Mar '24	Jun '24	Sep '24
net income	-7.65M -	-7.28M 4.81%	-8.66M 18.93%	-9.14M 5.52%	-11.22M 22.71%	-13.42M 19.61%	-13.42M 0%	-16.78M 25.09%
depreciation and amortization	97K -	86K 11.34%	100K 16.28%	83K 17%	92K 10.84%	97K 5.43%		135K -
deferred income tax
stock based compensation	941K -	484K 48.57%		541K -	606K 12.01%	2.18M 259.57%	2.18M 0%	2.00M 8.31%
change in working capital	818K -	-976K 219.32%	600K 161.48%	834K 39%	-1.16M 238.61%	-255K 77.94%		-1.18M -
accounts receivables	1.02M -	-37K 103.62%	67K 281.08%			8K -		-8K -
inventory
accounts payables	400K -	-649K 262.25%	1.44M 321.73%	-641K 144.54%	-781K 21.84%	1.12M 243.41%		409K -
other working capital		-290K -	-906K 212.41%			-1.38M -		-1.58M -
other non cash items	40K -	1.51M 3,670.00%	22K 98.54%	164K 645.45%	177K 7.93%	1.66M 836.72%		4.10M -
net cash provided by operating activities	-6.02M -	-7.52M 24.96%	-6.63M 11.82%	-7.76M 17.03%	-11.52M 48.41%	-10.98M 4.69%		-11.73M -
investments in property plant and equipment	-62K -	-21K 66.13%	-54K 157.14%	-43K 20.37%	-352K 718.60%	-224K 36.36%		-1.00M -
acquisitions net
purchases of investments
sales maturities of investments
other investing activites
net cash used for investing activites	-62K -	-21K 66.13%	-54K 157.14%	-43K 20.37%	-352K 718.60%	-224K 36.36%		-1.00M -
debt repayment
common stock issued	4K -	25M 624,900%	-51K 100.20%	152K 398.04%	29K 80.92%	134.56M 463,896.55%	141.48M 5.14%	3.25M 97.70%
common stock repurchased
dividends paid
other financing activites	-157K -				-1.90M -	-3.03M 59.73%		1.32M -
net cash used provided by financing activities	19.71M -	25M 26.83%	-51K 100.20%	49K 196.08%	43.13M 87,924.49%	134.56M 211.97%		1.32M -
effect of forex changes on cash	20K -	-19K 195%		18K -	4K 77.78%	-5K 225%		-7K -
net change in cash	13.65M -	17.44M 27.75%	-6.74M 138.66%	-7.74M 14.85%	31.26M 503.82%	123.35M 294.58%		-10.92M -
cash at beginning of period	34.70M -	48.34M 39.34%		59.03M -	51.29M 13.11%	82.55M 60.95%		193.12M -
cash at end of period	48.34M -	65.78M 36.07%	-6.74M 110.25%	51.29M 860.95%	82.55M 60.95%	205.90M 149.42%		182.20M -
operating cash flow	-6.02M -	-7.52M 24.96%	-6.63M 11.82%	-7.76M 17.03%	-11.52M 48.41%	-10.98M 4.69%		-11.73M -
capital expenditure	-62K -	-21K 66.13%	-54K 157.14%	-43K 20.37%	-352K 718.60%	-224K 36.36%		-1.00M -
free cash flow	-6.08M -	-7.54M 24.03%	-6.69M 11.35%	-7.81M 16.73%	-11.88M 52.10%	-11.21M 5.63%		-12.73M -

ANRO

COM:ALTONEUROSCIENCE

Alto Neuroscience

Last Close

4.09

22/11 21:00

Market Cap

104.91M

Beta: -

Volume Today

362.06K

Avg: -

Preview